WuHan Hvsen Biotechnology News

Huisheng Biotech (300871): Multiple factors influence short-term performance under pressure, and the recovery in farming sentiment drives a sharp rise in business volume and price

西南證券May 1 00:00

Huisheng Biotech (300871): Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals

國信證券Apr 28 00:00

Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low

Zhitong FinanceApr 25 19:59

Huisheng Biotech (300871) Company Review Report: The fixed increase plan highlights the company's confidence in development, the farming boom, and the company's priority benefits

方正證券Apr 7 20:56

Huisheng Biotech (300871): Revenue growth is steady and the API sector is relatively sluggish

興業證券Sep 7, 2023 18:16

Huisheng Biology (300871): Pharmaceutical business volume and profit improved +144% year-on-year in the first half of the year

國信證券Aug 30, 2023 07:16

Huisheng Biotech (300871): Q1's year-on-year profit improved sharply, and downstream sentiment is expected to pick up

興業證券Apr 28, 2023 00:00

Huisheng Biology (300871): Focus on veterinary chemicals for 20 years and forge a leader in veterinary chemical formulations

太平洋證券Nov 1, 2022 00:00

Huisheng Biology (300871): Focus on veterinary chemicals for 20 years and forge a leader in veterinary chemical formulations

太平洋證券Oct 28, 2022 00:00

Huisheng Bio (300871): profit elasticity release of downstream aquaculture continuous boom company

興業證券Oct 27, 2022 13:50

Comment on the third quarterly report of Huisheng Biological (300871) 2022: Q3 performance improved obviously under the improvement of both supply and demand profit gradually repaired.

民生證券Oct 27, 2022 00:00

Huisheng Bio (300871): revenue growth due to reversal of pig cycle gross profit margin of products has been repaired

太平洋證券Oct 25, 2022 00:00

Review of Huisheng Biological (300871) Quarterly report: Q3 income growth is in the stage of steady recovery.

國盛證券Oct 25, 2022 00:00

Huisheng Biological (300871) in-depth report: domestic veterinary drug preparation leading capacity expansion embrace cycle upward

民生證券Oct 20, 2022 19:21

Huisheng Bio (300871): downstream demand recovery performance elasticity is expected to recover

興業證券Sep 6, 2022 00:00

Huisheng Bio (300871): cost and depreciation suppress profitability in the second half of the year, the predicament reverses with strong certainty.

國盛證券Aug 31, 2022 18:37

Huisheng Bio (300871): demand improvement, economic recovery, recovery capacity release performance is expected

申港證券Aug 31, 2022 00:00

Huisheng Biological (300871): Q2 profit increased by 122% month-on-month, optimistic about the release of new production capacity.

國信證券Aug 30, 2022 12:56

Huisheng Bio (300871): the inflection point has reached the innovation-driven future

西南證券Aug 29, 2022 00:00

Huisheng Bio (300871): aquaculture warms up and superimposes production capacity to put veterinary drug preparation faucet or up-to-date.

國信證券Jul 16, 2022 00:00